USE OF SECONDARY LYMPHOID ORGAN CHEMOKINE TO INDUCE ANTI-TUMOR RESPONSE BY STIMULATING CELL-MEDIATED IMMUNE RESPONSE AND INHIBITING ANGIOGENESIS
| UCLA Technology Available For Licensing |
BACKGROUND: Chemokines are a group of homologous yet functionally divergent proteins that mediate leukocyte migration and activation and play a role in regulating angiogenesis. Secondary lymphoid organ chemokine (SLC, also referred to as Exodus-2 or 6Ckine) is a chemokine expressed by high endothelial venules in T-cell zones of spleen and lymph nodes. It strongly attracts naïve T-cells and mature dendritic cells to the initial site of immune activation.
INNOVATION: The present invention exploits the chemoattracting activity of SLC in co-localizing T lymphocytes and dendritic cells to potently enhance cell-mediated immunity against tumor cells and also takes advantage of SLC's anti-angiogenic activities. Using recombinant SLC, UCLA Researchers have demonstrated, in in vitro and in vivo models, that SLC mediates T cell-dependent anti-tumor responses.
ADVANTAGES
APPLICATIONS
DEVELOPMENT TO DATE: Intratumoral injection of recombinant SLC in mice leads to co-localization of both DC and T lymphocytes within tumor nodules and T cell dependent tumor rejection. Studies of SLC injected in the axillary lymph node region in the spontaneous lung cancer model leads to generation of systemic antitumor responses. Subsequent studies indicated that the antitumor properties of SLC are due to both its chemotatctic capacity in co-localizating DCs and T cells and its induction of key cytokines involved in cell-mediated responses.
Related Papers (Selected)
|
| Reference: UCLA Case No. 2001-381 | US Published Pat. Application: 20030175801 A1 |
|
availability, please contact the following UCLA office:
|
|
Copyright © 2003 The Regents of the University of California.